Company: SHPH
Filing Date: 2025-02-13
Form Type: S-1
Source: 0001493152-25-006202
Chunk: 67

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-13
Form: S-1
Chunk 67
---
-----------:|:--|:----|:--------------|-----------:|:--|:----|:--------------------------|-----------:|:--|:----|:-----|-----------:|:--|
| Operating expenses                                             |     | $                   |  5,892,382 |   |     | $             |  2,343,826 |   |     | $                         |  5,919,042 |   |     | $    |  4,609,558 |   |
| Loss from operations                                           |     | $                   | (5,892,382 | ) |     | $             | (2,343,826 | ) |     | $                         | (5,919,042 | ) |     | $    | (4,609,558 | ) |
| Other income (expense)                                         |     | $                   |   (700,341 | ) |     | $             | (2,652,243 | ) |     | $                         | (1,627,286 | ) |     | $    |   (342,665 | ) |
| Net loss                                                       |     | $                   | (6,592,723 | ) |     | $             | (4,996,069 | ) |     | $                         | (7,546,328 | ) |     | $    | (4,952,223 | ) |
| Weighted average common shares outstanding – basic and diluted |     |                     |  1,886,275 |   |     |               |  1,337,742 |   |     |                           |  2,189,366 |   |     |      |  1,820,006 |   |
| Net loss per share – basic and diluted                         |     | $                   |      (3.53 | ) |     | $             |      (5.04 | ) |     | $                         |      (3.45 | ) |     | $    |      (2.72 | ) |

<div align='center'>USE OF PROCEEDS</div>

We estimate that the net proceeds from this offering, after deducting underwriting fees and estimated offering expenses payable by us, will be approximately $[*] million (based on an assumed public offering price of $[*] per common stock, which was the last reported sales price of our common stock on Nasdaq on February [*], 2025, and assuming that all shares of